The primary types of non-corticosteroid immunomodulators include, calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, and IMDH inhibitors among other drug classes.This is a drug class that inhibits the cell-cycle pathways to limit T- and B-cell proliferation to reduce the cytotoxic response directed toward an organ transplant such as cardiac allograft.
Market Analysis and Insights: Global Non-corticosteroid Immunomodulator Market
The global Non-corticosteroid Immunomodulator market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Non-corticosteroid Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Non-corticosteroid Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Non-corticosteroid Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Non-corticosteroid Immunomodulator include Accord Healthcare, Bristol-Myers Squibb Company, Astella Pharma, Genzyme Co., GlaxoSmithKline PLC, Merck KGaA, Glenmark Pharmaceuticals, Inc., Pfizer Inc. and Mylan Laboratories Inc., etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Non-corticosteroid Immunomodulator market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Non-corticosteroid Immunomodulator, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Non-corticosteroid Immunomodulator, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non-corticosteroid Immunomodulator revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Non-corticosteroid Immunomodulator market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Non-corticosteroid Immunomodulator revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Accord Healthcare, Bristol-Myers Squibb Company, Astella Pharma, Genzyme Co., GlaxoSmithKline PLC, Merck KGaA, Glenmark Pharmaceuticals, Inc., Pfizer Inc. and Mylan Laboratories Inc., etc.
By Company
Accord Healthcare
Bristol-Myers Squibb Company
Astella Pharma
Genzyme Co.
GlaxoSmithKline PLC
Merck KGaA
Glenmark Pharmaceuticals, Inc.
Pfizer Inc.
Mylan Laboratories Inc.
Actavis, Inc.
Novartis AG
Zydus Cadila
Segment by Type
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitors
IMDH Inhibitors
Others
Segment by Application
Organ Transplantation
Atopic Dermatitis
Crohn’s Disease
Ulcerative Colitis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Non-corticosteroid Immunomodulator in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-corticosteroid Immunomodulator companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-corticosteroid Immunomodulator revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-corticosteroid Immunomodulator Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Calcineurin Inhibitors
1.2.3 Antiproliferative Agents
1.2.4 mTOR Inhibitors
1.2.5 IMDH Inhibitors
1.2.6 Others
1.3 Market by Application
1.3.1 Global Non-corticosteroid Immunomodulator Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Organ Transplantation
1.3.3 Atopic Dermatitis
1.3.4 Crohn’s Disease
1.3.5 Ulcerative Colitis
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-corticosteroid Immunomodulator Market Perspective (2018-2029)
2.2 Global Non-corticosteroid Immunomodulator Growth Trends by Region
2.2.1 Non-corticosteroid Immunomodulator Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-corticosteroid Immunomodulator Historic Market Size by Region (2018-2023)
2.2.3 Non-corticosteroid Immunomodulator Forecasted Market Size by Region (2024-2029)
2.3 Non-corticosteroid Immunomodulator Market Dynamics
2.3.1 Non-corticosteroid Immunomodulator Industry Trends
2.3.2 Non-corticosteroid Immunomodulator Market Drivers
2.3.3 Non-corticosteroid Immunomodulator Market Challenges
2.3.4 Non-corticosteroid Immunomodulator Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Non-corticosteroid Immunomodulator by Players
3.1.1 Global Non-corticosteroid Immunomodulator Revenue by Players (2018-2023)
3.1.2 Global Non-corticosteroid Immunomodulator Revenue Market Share by Players (2018-2023)
3.2 Global Non-corticosteroid Immunomodulator Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Non-corticosteroid Immunomodulator, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Non-corticosteroid Immunomodulator Market Concentration Ratio
3.4.1 Global Non-corticosteroid Immunomodulator Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-corticosteroid Immunomodulator Revenue in 2022
3.5 Global Key Players of Non-corticosteroid Immunomodulator Head office and Area Served
3.6 Global Key Players of Non-corticosteroid Immunomodulator, Product and Application
3.7 Global Key Players of Non-corticosteroid Immunomodulator, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-corticosteroid Immunomodulator Breakdown Data by Type
4.1 Global Non-corticosteroid Immunomodulator Historic Market Size by Type (2018-2023)
4.2 Global Non-corticosteroid Immunomodulator Forecasted Market Size by Type (2024-2029)
5 Non-corticosteroid Immunomodulator Breakdown Data by Application
5.1 Global Non-corticosteroid Immunomodulator Historic Market Size by Application (2018-2023)
5.2 Global Non-corticosteroid Immunomodulator Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Non-corticosteroid Immunomodulator Market Size (2018-2029)
6.2 North America Non-corticosteroid Immunomodulator Market Size by Type
6.2.1 North America Non-corticosteroid Immunomodulator Market Size by Type (2018-2023)
6.2.2 North America Non-corticosteroid Immunomodulator Market Size by Type (2024-2029)
6.2.3 North America Non-corticosteroid Immunomodulator Market Share by Type (2018-2029)
6.3 North America Non-corticosteroid Immunomodulator Market Size by Application
6.3.1 North America Non-corticosteroid Immunomodulator Market Size by Application (2018-2023)
6.3.2 North America Non-corticosteroid Immunomodulator Market Size by Application (2024-2029)
6.3.3 North America Non-corticosteroid Immunomodulator Market Share by Application (2018-2029)
6.4 North America Non-corticosteroid Immunomodulator Market Size by Country
6.4.1 North America Non-corticosteroid Immunomodulator Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Non-corticosteroid Immunomodulator Market Size by Country (2018-2023)
6.4.3 North America Non-corticosteroid Immunomodulator Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Non-corticosteroid Immunomodulator Market Size (2018-2029)
7.2 Europe Non-corticosteroid Immunomodulator Market Size by Type
7.2.1 Europe Non-corticosteroid Immunomodulator Market Size by Type (2018-2023)
7.2.2 Europe Non-corticosteroid Immunomodulator Market Size by Type (2024-2029)
7.2.3 Europe Non-corticosteroid Immunomodulator Market Share by Type (2018-2029)
7.3 Europe Non-corticosteroid Immunomodulator Market Size by Application
7.3.1 Europe Non-corticosteroid Immunomodulator Market Size by Application (2018-2023)
7.3.2 Europe Non-corticosteroid Immunomodulator Market Size by Application (2024-2029)
7.3.3 Europe Non-corticosteroid Immunomodulator Market Share by Application (2018-2029)
7.4 Europe Non-corticosteroid Immunomodulator Market Size by Country
7.4.1 Europe Non-corticosteroid Immunomodulator Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Non-corticosteroid Immunomodulator Market Size by Country (2018-2023)
7.4.3 Europe Non-corticosteroid Immunomodulator Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Non-corticosteroid Immunomodulator Market Size (2018-2029)
8.2 China Non-corticosteroid Immunomodulator Market Size by Type
8.2.1 China Non-corticosteroid Immunomodulator Market Size by Type (2018-2023)
8.2.2 China Non-corticosteroid Immunomodulator Market Size by Type (2024-2029)
8.2.3 China Non-corticosteroid Immunomodulator Market Share by Type (2018-2029)
8.3 China Non-corticosteroid Immunomodulator Market Size by Application
8.3.1 China Non-corticosteroid Immunomodulator Market Size by Application (2018-2023)
8.3.2 China Non-corticosteroid Immunomodulator Market Size by Application (2024-2029)
8.3.3 China Non-corticosteroid Immunomodulator Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Non-corticosteroid Immunomodulator Market Size (2018-2029)
9.2 Asia Non-corticosteroid Immunomodulator Market Size by Type
9.2.1 Asia Non-corticosteroid Immunomodulator Market Size by Type (2018-2023)
9.2.2 Asia Non-corticosteroid Immunomodulator Market Size by Type (2024-2029)
9.2.3 Asia Non-corticosteroid Immunomodulator Market Share by Type (2018-2029)
9.3 Asia Non-corticosteroid Immunomodulator Market Size by Application
9.3.1 Asia Non-corticosteroid Immunomodulator Market Size by Application (2018-2023)
9.3.2 Asia Non-corticosteroid Immunomodulator Market Size by Application (2024-2029)
9.3.3 Asia Non-corticosteroid Immunomodulator Market Share by Application (2018-2029)
9.4 Asia Non-corticosteroid Immunomodulator Market Size by Region
9.4.1 Asia Non-corticosteroid Immunomodulator Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Non-corticosteroid Immunomodulator Market Size by Region (2018-2023)
9.4.3 Asia Non-corticosteroid Immunomodulator Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Type
10.2.1 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Application
10.3.1 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Country
10.4.1 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Non-corticosteroid Immunomodulator Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Accord Healthcare
11.1.1 Accord Healthcare Company Details
11.1.2 Accord Healthcare Business Overview
11.1.3 Accord Healthcare Non-corticosteroid Immunomodulator Introduction
11.1.4 Accord Healthcare Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.1.5 Accord Healthcare Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Details
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Non-corticosteroid Immunomodulator Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.2.5 Bristol-Myers Squibb Company Recent Developments
11.3 Astella Pharma
11.3.1 Astella Pharma Company Details
11.3.2 Astella Pharma Business Overview
11.3.3 Astella Pharma Non-corticosteroid Immunomodulator Introduction
11.3.4 Astella Pharma Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.3.5 Astella Pharma Recent Developments
11.4 Genzyme Co.
11.4.1 Genzyme Co. Company Details
11.4.2 Genzyme Co. Business Overview
11.4.3 Genzyme Co. Non-corticosteroid Immunomodulator Introduction
11.4.4 Genzyme Co. Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.4.5 Genzyme Co. Recent Developments
11.5 GlaxoSmithKline PLC
11.5.1 GlaxoSmithKline PLC Company Details
11.5.2 GlaxoSmithKline PLC Business Overview
11.5.3 GlaxoSmithKline PLC Non-corticosteroid Immunomodulator Introduction
11.5.4 GlaxoSmithKline PLC Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.5.5 GlaxoSmithKline PLC Recent Developments
11.6 Merck KGaA
11.6.1 Merck KGaA Company Details
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Non-corticosteroid Immunomodulator Introduction
11.6.4 Merck KGaA Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.6.5 Merck KGaA Recent Developments
11.7 Glenmark Pharmaceuticals, Inc.
11.7.1 Glenmark Pharmaceuticals, Inc. Company Details
11.7.2 Glenmark Pharmaceuticals, Inc. Business Overview
11.7.3 Glenmark Pharmaceuticals, Inc. Non-corticosteroid Immunomodulator Introduction
11.7.4 Glenmark Pharmaceuticals, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.7.5 Glenmark Pharmaceuticals, Inc. Recent Developments
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Non-corticosteroid Immunomodulator Introduction
11.8.4 Pfizer Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.8.5 Pfizer Inc. Recent Developments
11.9 Mylan Laboratories Inc.
11.9.1 Mylan Laboratories Inc. Company Details
11.9.2 Mylan Laboratories Inc. Business Overview
11.9.3 Mylan Laboratories Inc. Non-corticosteroid Immunomodulator Introduction
11.9.4 Mylan Laboratories Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.9.5 Mylan Laboratories Inc. Recent Developments
11.10 Actavis, Inc.
11.10.1 Actavis, Inc. Company Details
11.10.2 Actavis, Inc. Business Overview
11.10.3 Actavis, Inc. Non-corticosteroid Immunomodulator Introduction
11.10.4 Actavis, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.10.5 Actavis, Inc. Recent Developments
11.11 Novartis AG
11.11.1 Novartis AG Company Details
11.11.2 Novartis AG Business Overview
11.11.3 Novartis AG Non-corticosteroid Immunomodulator Introduction
11.11.4 Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.11.5 Novartis AG Recent Developments
11.12 Zydus Cadila
11.12.1 Zydus Cadila Company Details
11.12.2 Zydus Cadila Business Overview
11.12.3 Zydus Cadila Non-corticosteroid Immunomodulator Introduction
11.12.4 Zydus Cadila Revenue in Non-corticosteroid Immunomodulator Business (2018-2023)
11.12.5 Zydus Cadila Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Accord Healthcare
Bristol-Myers Squibb Company
Astella Pharma
Genzyme Co.
GlaxoSmithKline PLC
Merck KGaA
Glenmark Pharmaceuticals, Inc.
Pfizer Inc.
Mylan Laboratories Inc.
Actavis, Inc.
Novartis AG
Zydus Cadila
*If Applicable.